PharmaCyte net loss widens to $19.42 million in FY26; revenue remains no revenue

• PharmaCyte Biotech posted a net loss of USD 19.42 million for fiscal 2026, swinging from net income of USD 30.66 million a year earlier.
• Other income fell to a net expense of USD 12.57 million from net income of USD 35.03 million, driven by fair-value losses on QCLS and warrant positions.
• Operating expenses climbed 56.5% to USD 6.85 million, including a USD 1.55 million impairment charge; R&D spending edged down to USD 391,301.
• Cash and cash equivalents rose to USD 18.6 million, while working capital increased to USD 36.6 million.
• The company continues work to lift the FDA clinical hold on its IND for a planned locally advanced pancreatic cancer trial using Cell-in-a-Box encapsulated live cells.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PharmaCyte Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-005836), on July 29, 2026, and is solely responsible for the information contained therein.